FirstWord: Market Research Reports

... provide their candid insights on the sequencing of novel targeted therapies in CLL, availability of real-world data and the future of chemotherapies. Business ... KOLs require clinical studies to demonstrate the similarity of Truxima to rituximab in CLL? If so, what studies are required? How comfortable are KOLs in extrapolating ...

... presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data ...

... presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating ...

... (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers Squibb’s Opdivo (nivolumab) for the second-line treatment of HNSCC, in April 2017 ... cancers, including HNSCC. Business Questions In March 2017, the EU’s CHMP recommended approval of Bristol-Myers Squibb’s Opdivo for the treatment of HNSCC, but how ...

... of its investigational intratumoral therapy, ImmunoPulse IL-12, with Keytruda (pembrolizumab) in metastatic melanoma patients who are not expected to respond to anti-PD-1 agents. Business ... NDA for binimetinib as monotherapy in NRAS melanoma the right one? Does binimetinib have a future in NRAS melanoma? Is there room for the market ...

... events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus ...

... on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar ... in the first-line treatment of ALK-positive NSCLC? How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events ...

... ’s Olumiant (baricitinib) gaining marketing authorisation in the EU. Business Questions How do payers intend to cover sarilumab? Will there be any restrictions? Is sarilumab likely ... over biosimilars of Humira? How are biosimilars of Remicade viewed by payers? Are payers surprised that baricitinib was declined approval in the US, but not ...

... views on how anti-IL5 mAbs are likely to fair in the COPD treatment paradigm, as well as provide insights on next-generation therapies and ... > Top Takeaways Is it all change in the COPD treatment paradigm? Three products have dominated the COPD treatment landscape over the past decade ... have on treatment practice? New guidelines on COPD patient assessment, segmentation and treatment were published in 2017, but what will be the ‘real-world ...

... In How Payers Want to Work with Pharma, 10 US and EU payers with expertise in formulary decision making and healthcare strategy reveal insights that will radically improve your payer ... Payers want additional data during clinical trial process where possible Roadblocks to using data include lack of context and potential for bias Payers ...

... market, where one brand is poised to nearly double its market share. Find out which barriers are costing your brand market share Market Access Impact: RCC (EU5). Based ... (pazopanib; Novartis) Exploring Market Access Barriers Market Access Impact: RCC (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... keeping doctors from prescribing your brand? Get the answers in Market Access Impact: RCC (US). Based on a survey of 100 medical oncologists, the report covers 10 major ... (pazopanib; Novartis) Exploring Market Access Barriers Market Access Impact: RCC (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... specialists we surveyed say medical affairs teams for 9 major HIV treatments could be doing a better job. They identified specific medical affairs services where teams are ... your team gets right, and where it’s going wrong in Medical Affairs Reputations: HIV (EU5). Comparing 9 major HIV treatments from Bristol-Myers Squibb, Gilead, Janssen Cilag ...

Survey shows medical affairs teams must be more active and provide better information Doctors say medical affairs teams for 10 major HIV treatments could be doing ... your team gets right, and where it’s going wrong in Medical Affairs Reputations: HIV (US). Comparing 10 major HIV treatments from Bristol-Myers Squibb, Gilead, Janssen, Merck ...

... they need to know about how their brand is being perceived in NPS+ Asthma/COPD (EU5). This report reveals satisfaction levels, message association for key ... Brand Loyalty Issues NPS+ Asthma/COPD (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing asthma/COPD drugs. You’ll discover ...

... they need to know about how their brand is being perceived in NPS+ Asthma/COPD (US). This report reveals satisfaction levels, message association for key ... Brand Loyalty Issues NPS+ Asthma/COPD (US) offers valuable insight into brand loyalty from the perspective of those currently prescribing asthma/COPD drugs to patients. You ...

... an alternative to chemotherapy in the treatment of relapsed BRCA-mutated high-grade ovarian cancer? How will recently approved Zejula compete with the existing ... term outlook for Avastin in ovarian cancer? How do KOLs view the combination of cediranib with Lynparza as a treatment for recurrent ovarian cancer? Quotes “Some of these ...

... Biogen could retain market share of Tecfidera. Business Questions: How do payers react to the recent approval of ocrelizumab? How is ocrelizumab likely to be covered ... ? Are there any apprehensions? How do payers react to the delay in launch of generic Copaxone 40mg/ml? According to payers, what can Teva do to retain its ...

... ) (PSA-TRICOM) in prostate cancer. Business Questions: How do KOLs view the biomarker-driven data published for AstraZeneca’s olaparib in prostate cancer? What are KOL ... ’s atezolizumab? Where will immunotherapy combinations be best utilised in patients with prostate cancer? What are KOL expectations for Bavarian Nordic’s PROSPECT study ...

... opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new ... guselkumab; efficacy, dosing or both? Where will guselkumab be used in the psoriasis treatment paradigm, or is it too early to tell? What could get in the ...

... are payers by Real World Data (RWD)? Is the evidence being provided matching their needs – or is it missing the point? Report Overview Real World Data: Meeting Payer Needs offers ... objectives and methodology Experts interviewed for this report Defining real-world data How real-world data could ease pressure on drug budgets Key insights Pharmaceutical ...

... 2017, Teva presented data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant improvement in symptoms with reslizumab therapy ...

... opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new ... KOLs react to the early stage data for ALX-0761? Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement ...

... planning biobetter development programmes HEOR teams building evidence of value for biobetter therapies MSL teams needing to demonstrate the clinical advantages of biobetters to physicians ... biobetter market Content Highlights Executive Summary & Experts interviewed The emergence of biobetters The biosimilar struggle Introducing biobetters Biobetters vs. biosimilars The biobetter advantage Marketing acceptance of biobetters ...

... /developers are setting the pace? Charting the Orphan Drug Development Pipeline analyses 3,868 unique molecules from 2,257 developers to create the most comprehensive independent analysis of orphan drug ... Overview Orphan drug market dynamics Legal definitions and incentives for orphan drug development in US and EU Trends in orphan drug designation For each therapy area covered EU/US designated drugs Orphan drugs designated ...

... have on market share? Are newer players changing market dynamics? Use this latest report to understand the barriers driving market share shifts. Market Access Impact: HIV (EU5) features 9 big-hitter named HIV drugs ...

... players changing market dynamics? Use this latest report to understand the barriers driving market share shifts. Market Access Impact: HIV (US) features 10 big-hitter HIV drugs from ... on Market Access issues Market Access Impact: HIV gives a unique insight into the issues affecting the major HIV drug manufacturers. You’ll learn: How barriers affect market access: Which HIV ...

... do to boost your team’s performance and satisfaction scores in Medical Affairs Reputations: RCC (US). Comparing 9 major RCC treatments from Bayer, Bristol-Myers Squibb, Exelixis, ... Interviews with Practicing Doctors We surveyed 150 oncologists from the EU5 (France, Italy, Germany, Spain, UK)— chosen from the ...

... for medical affairs teams involve providing information doctors can use to make better treatment decisions. Insight into Medical Affairs Teams for These RCC Treatments ... with RCC in a typical month Devote at least 50% of their time to direct patient care Have interacted with at least one listed product’s medical affairs team ...

... can do to boost your score in FirstView’s NPS+ Psoriasis 2017 (EU5). Building on the respected net promoter score (NPS), the report compares ten major ... ) A Report Based on Expert Knowledge We surveyed 150 dermatologists from the EU5 countries (France, Italy, Germany, Spain, UK), chosen from the largest ... and 8th, 2017. Explore Important Brand Loyalty Issues NPS+ Psoriasis 2017 (EU5) explores key issues affecting brand loyalty for drug ...

... article One Number You Need to Grow. How does NPS work? NPS measures overall brand satisfaction and loyalty by asking one simple ... percentage of detractors - the percentage of promoters = NPS. For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5. NPS can range from -100 (everybody ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...

... the data puzzle with innovative contracts Key Insights Innovative contracting solutions Opportunities in innovative contracting Key factors to pull the data puzzle together Key Insights Data capabilities and infrastructure People, positions and partnerships A culture of payer-centricity Enhancing the data puzzle Key Insights ...

... Research Center in Dallas, TX. KOLs from Europe Prof Paul Emery. Arthritis Research UK Professor of Rheumatology and Director of the Leeds Institute of Rheumatic ...

... payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis ( ... According to payers, what can Biogen do to retain market share of Tecfidera? Update Bulletins include expert insight and analysis based ...

... KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy of Allergy, Asthma ... controlled asthma and aspirin sensitivity received significant improvement in symptoms with reslizumab therapy, but ...

... emerging-market industry Pipeline of biosimilar monoclonal antibodies in emerging markets Pipeline of non-monoclonal antibody biosimilars in emerging markets In market access, biosimilar players face different challenges to originators Funding & pricing attributes of leading emerging markets ...

... cell carcinoma (HNSCC) in the US and further immunotherapy approvals are expected to fuel the continuing evolution of the treatment algorithm. KOL’s weigh in on the ... key clinical trials set to shape treatment decisions in HNSCC? 6 US and 6 EU KOLs offer their candid insights on these issues and more Take a tour of the ...

... pack. Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5). Based on a survey of 150 dermatologists, the ... Lilly) Exploring Important Market Access Issues Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands ...

... holding your brand back, and what you can do about it, in Market Access Impact: Psoriasis (US). Based on a survey of 100 dermatologists, the report covers 8 major ... Lilly) Exploring Market Access Barriers Market Access Impact: Psoriasis (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands do doctors ...

... survey of 150 medical oncologists shows that they’re hungry for information, and feel that EU5-based medical affairs teams for leading NSCLC treatments should ... can do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (EU5). Comparing 10 major NSCLC treatments from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb ...

... do to move your team ahead of its closest rivals in Medical Affairs Reputations: NSCLC (EU5). Comparing 10 major NSCLC treatments from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb ... must improve the same medical affairs service to boost their satisfaction scores. Insight into Medical Affairs Teams for These NSCLC Treatments Avastin (bevacizumab; Roche ...

... HIV treatments, but satisfaction runs highest for 2 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 150 EU5 ... score in FirstView’s NPS+ HIV 2017 (EU5). Building on the respected net promoter score (NPS), the report compares loyalty for nine major HIV drugs. Easy ... and 8th, 2017. Explore Important Brand Loyalty Issues NPS+ HIV 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...

... score in FirstView’s NPS+ HIV 2017 (US). Building on the respected net promoter score (NPS), the report compares loyalty for ten major HIV drugs. Easy ... on average. Cost is not a strong driver of recommendations. Insight into 10 Major HIV Brands Descovy (emtricitabine/tenofovir alafenamide; Gilead) Genvoya (cobicistat/elvitegravir ... Issues NPS+ HIV 2017 (US) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn: How satisfied doctors are with HIV ...

... account context Data and analysis: no single approach dominates Capability: More to do Plans for the future: Increasing investment in Real World Data and Real World Evidence Benchmarking Real World Data and collaboration Key findings The need to work together The future for RWD Key findings Real World Data and Real World Evidence ...

... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Acute Myeloid Leukaemia (AML). Twelve US and European KOLs give their insight on two off-label marketed products and 16 pipeline programmes. KOLs also ...

... life expectancy of ~40 years? Learn how KOLs see the CF market evolving in KOL Insight: Cystic Fibrosis (CF). 12 US and European KOLs provide candid insights on 4 marketed and 12 emerging therapies targeting ... full list now Sample of KOLs interviewed KOLs from North America Dr Patrick Flume, MD, Powers-Huggins Endowed Chair for Cystic Fibrosis, Professor of Medicine and ...

... up the top and middle of the market, and help the last place brand double its share in Market Access Impact: Melanoma (US). Based on a survey of 150 oncologists ... ; Roche) Exploring Important Market Access Issues Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You’ll learn: How barriers affect market access What brands do doctors ...

... , and what your brand can do to level the playing field in Market Access Impact: Melanoma (US). Based on a survey of 100 oncologists and dermato-oncologists, the report ... (vemurafenib; Roche) Exploring Market Access Barriers Market Access Impact: Melanoma (US) explores key issues affecting melanoma drug manufacturers. You’ll learn: How barriers affect market access What brands do doctors ...

Compare 10 psoriasis medical affairs teams. See how your team stacks up to the market leader In the EU5, several of the psoriasis medical affairs teams we surveyed are ... ?” Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Psoriasis (EU5). Purchase your copy now Comparing 10 major Psoriasis treatments ...

... improve your medical affair services in Medical Affairs Reputations: Psoriasis (US). Purchase your copy now Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: Psoriasis ... Competitive View of Your Medical Affairs Team Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important ...